You are on page 1of 1

Cert. No.

M0577

CLIENT CODE : C000024536


CLIENT'S NAME AND ADDRESS :
RAKESH RANI

SRL LIMITED(Formerly known as Super Religare Laboratories Limited)


24 SCO, SECTOR 11 D
CHANDIGARH, 160011
PUNJAB, INDIA
Tel : 0172-4061121-22, Fax :
CIN - U74899DL1995PLC070603

PATIENT ID :

PATIENT NAME : RAKESH RANI


ACCESSION NO :
DRAWN :

0080NK004036

19/11/2014 10:29

AGE :

60 Years

RECEIVED :

SEX : Female

19/11/2014 10:31

DATE OF BIRTH :
REPORTED :

REFERRING DOCTOR : DR. PGI

Test Report Status

RAKEF19115480

19/11/2014 12:34

CLIENT PATIENT ID :

Results

Final

Biological Reference Interval

Units

COAGULATION
PROTHROMBIN TIME, PLASMA
PROTHROMBIN TIME (PT)

13.5

High 9.8 - 12.1

SECONDS

METHOD : OPTICAL DETECTION METHOD

INTERNATIONAL NORMALIZED RATIO (INR)

1.1

RATIO

11.6

SECONDS

METHOD : CALCULATED PARAMETER

MEAN NORMAL PT
METHOD : CALCULATED PARAMETER

Comments
PTI=85.9%
Test Method(s)
PROTHROMBIN TIME, PLASMAPROTHROMBIN TIME (PT), PLASMA
Prothrombin Time measures the integrity of the extrinsic pathway and the adequacy of critical coagulation factors involved in it, namely, Factor VII. This test is therefore,
used for monitoring oral anticoagulation therapy which lowers the levels of multiple vitamin K dependent coagulation factors in blood (Factors II, VII, IX and X) including
Factor VII. The result of PT is expressed as International Normalized Ratio (INR) to neutralize the influence of variable sensitivity of the reagents (thromboplastin) used in the
assay by different laboratories.
Prolonged PT/INR is observed in hereditary or acquired deficiency of the relevant coagulation factors, vitamin K deficiency, liver disease, specific coagulation factor inhibitors
and nonspecific inhibitors of PT (eg, monoclonal immunoglobulins, elevated fibrin degradation products).
The following INR ranges are recommended for achieving optimal anticoagulation in different clinical conditions:
Diagnosis

Target INR

Treatment of venous thrombosis


Treatment of pulmonary embolism
Prevention of systemic embolism
Tissue heart valves
Hypercoagulable states
Atrial fibrillation
Mechanical prosthetic valves (high risk)
Bileaflet mechanical valve in aortic position

2.0 - 3.0
2.0 - 3.0
2.0 - 3.0
2.0 - 3.0
2.0 - 3.0
2.0 - 3.0
2.5 - 3.5
2.0 - 3.0

**End Of Report**
Please visit www.srlworld.com for related Test Information for this accession

Dr. Maneesh Bagai, MD


Pathologist

Dr. Shailja
Pathologist

Page 1 Of 1